Minerva Neurosciences Forms Scientific Advisory Board to Guide Roluperidone Development
Event summary
- Minerva Neurosciences established a Scientific Advisory Board (SAB) on June 1, 2026, fulfilling a commitment from its October 2025 PIPE financing.
- The SAB includes seven distinguished researchers and clinicians specializing in psychiatry and neuroscience.
- The board will advise on the Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline data expected in late 2027.
- Roluperidone is the only monotherapy treatment to show significant improvements in negative symptoms of schizophrenia in prior trials.
The big picture
Minerva's move to establish a high-profile SAB underscores the strategic importance of roluperidone, particularly as it targets an unmet need in schizophrenia treatment. The board's expertise could accelerate development timelines and strengthen regulatory filings, though the company's ability to execute on these plans will depend on trial outcomes and funding stability. The formation also signals Minerva's intent to build a robust pipeline beyond its lead candidate.
What we're watching
- Clinical Trial Execution
- The success of the Phase 3 trial will hinge on enrollment rates and the ability to demonstrate efficacy over placebo.
- Regulatory Pathway
- The FDA's stance on negative symptom treatments will be critical for roluperidone's approval prospects.
- Pipeline Development
- The SAB's influence on Minerva's broader pipeline could shape its long-term strategy in psychiatric disorders.